APA (7th ed.) Citation

DA, C., VA, P., SA, S., LN, B., LA, S., & VV, N. (2011). The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel. Acta diabetologica, 48(3), 227. https://doi.org/10.1007/s00592-011-0299-4

Chicago Style (17th ed.) Citation

DA, Chistiakov, Potapov VA, Smetanina SA, Bel'chikova LN, Suplotova LA, and Nosikov VV. "The Carriage of Risk Variants of CDKAL1 Impairs Beta-cell Function in Both Diabetic and Non-diabetic Patients and Reduces Response to Non-sulfonylurea and Sulfonylurea Agonists of the Pancreatic KATP Channel." Acta Diabetologica 48, no. 3 (2011): 227. https://doi.org/10.1007/s00592-011-0299-4.

MLA (9th ed.) Citation

DA, Chistiakov, et al. "The Carriage of Risk Variants of CDKAL1 Impairs Beta-cell Function in Both Diabetic and Non-diabetic Patients and Reduces Response to Non-sulfonylurea and Sulfonylurea Agonists of the Pancreatic KATP Channel." Acta Diabetologica, vol. 48, no. 3, 2011, p. 227, https://doi.org/10.1007/s00592-011-0299-4.